Tassilo L A Wachsmann, Teuntje Poortvliet, Miranda H Meeuwsen, Dennis F G Remst, Marijke F Toes, Anne K Wouters, Renate S Hagedoorn, J H Frederik Falkenburg, Mirjam H M Heemskerk
{"title":"CAR-mediated target recognition limits TCR-mediated target recognition of TCR- and CAR-dual-receptor-edited T cells.","authors":"Tassilo L A Wachsmann, Teuntje Poortvliet, Miranda H Meeuwsen, Dennis F G Remst, Marijke F Toes, Anne K Wouters, Renate S Hagedoorn, J H Frederik Falkenburg, Mirjam H M Heemskerk","doi":"10.1016/j.ymthe.2025.02.035","DOIUrl":null,"url":null,"abstract":"<p><p>Antigen escape can compromise the efficacy of chimeric antigen receptor- (CAR-) or T cell receptor- (TCR-) engineered T cells. Targeting multiple antigens can effectively limit antigen escape, and combining CAR-with TCR-mediated targeting can significantly broaden the spectrum of targetable antigens. Here, we explored whether dual-antigen specificity can be installed on T cells using combined TCR and CAR engineering to prevent antigen escape of multiple myeloma (MM). We report the generation of CD8 T cells that were transduced to express a transgenic TCR, targeting a peptide derived from transcriptional coactivator BOB1 in the context of HLA-B∗07:02, alongside a BCMA-targeting CAR. Those T cells, called TRaCR T cells, efficiently recognized target cells that were resistant to either BOB1 TCR or BCMA CAR T cells, illustrating general dual specificity. In the presence of both antigens, however, target cell recognition was preferentially conferred via the CAR, compromising TCR-mediated target cell recognition. Importantly, this resulted in a survival advantage for tumor cells lacking expression of BCMA in an in vivo model of heterogeneous MM. In conclusion, we demonstrate general dual specificity of TRaCR T cells but advise caution when using TRaCR T cells as a strategy to target heterogeneous tumors.</p>","PeriodicalId":19020,"journal":{"name":"Molecular Therapy","volume":" ","pages":"1642-1658"},"PeriodicalIF":12.0000,"publicationDate":"2025-04-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11997489/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Molecular Therapy","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1016/j.ymthe.2025.02.035","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/2/28 0:00:00","PubModel":"Epub","JCR":"Q1","JCRName":"BIOTECHNOLOGY & APPLIED MICROBIOLOGY","Score":null,"Total":0}
引用次数: 0
Abstract
Antigen escape can compromise the efficacy of chimeric antigen receptor- (CAR-) or T cell receptor- (TCR-) engineered T cells. Targeting multiple antigens can effectively limit antigen escape, and combining CAR-with TCR-mediated targeting can significantly broaden the spectrum of targetable antigens. Here, we explored whether dual-antigen specificity can be installed on T cells using combined TCR and CAR engineering to prevent antigen escape of multiple myeloma (MM). We report the generation of CD8 T cells that were transduced to express a transgenic TCR, targeting a peptide derived from transcriptional coactivator BOB1 in the context of HLA-B∗07:02, alongside a BCMA-targeting CAR. Those T cells, called TRaCR T cells, efficiently recognized target cells that were resistant to either BOB1 TCR or BCMA CAR T cells, illustrating general dual specificity. In the presence of both antigens, however, target cell recognition was preferentially conferred via the CAR, compromising TCR-mediated target cell recognition. Importantly, this resulted in a survival advantage for tumor cells lacking expression of BCMA in an in vivo model of heterogeneous MM. In conclusion, we demonstrate general dual specificity of TRaCR T cells but advise caution when using TRaCR T cells as a strategy to target heterogeneous tumors.
期刊介绍:
Molecular Therapy is the leading journal for research in gene transfer, vector development, stem cell manipulation, and therapeutic interventions. It covers a broad spectrum of topics including genetic and acquired disease correction, vaccine development, pre-clinical validation, safety/efficacy studies, and clinical trials. With a focus on advancing genetics, medicine, and biotechnology, Molecular Therapy publishes peer-reviewed research, reviews, and commentaries to showcase the latest advancements in the field. With an impressive impact factor of 12.4 in 2022, it continues to attract top-tier contributions.